or Try an Advanced Search...

    Technical Analysis for IMNM - Immunome, Inc.

    Grade Last Price % Change Price Change
    D 14.26 -0.07% -0.01
    IMNM closed down 0.07 percent on Thursday, April 25, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 3
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical IMNM trend table...
    Date Alert Name Type % Chg
    Doji - Bullish? Reversal 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New Downtrend Bearish -0.07%
    NR7 Range Contraction -0.07%
    Wide Bands Range Expansion -0.07%
    Down 3 Days in a Row Weakness -0.07%
    Older End-of-Day Signals for IMNM ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 16 hours ago
    Down 3% about 16 hours ago
    Fell Below Previous Day's Low about 16 hours ago
    Down 2 % about 16 hours ago
    Down 1% about 16 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    IMNM Chart by TradingView
    Basic chart:

    Profile

    Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Clinical Medicine Immunology Immune System Antibodies Tumor Cancer Immunotherapy Monoclonal Antibodies Monoclonal Antibody Antibody Glycoproteins Antigen Symphogen

    Is IMNM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 25 Immunome Appoints Sandra M. Swain to Board of Directors
    Apr 5 Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
    Apr 4 New Strong Sell Stocks for April 4th
    Apr 3 Immunome files to sell 2.18M common shares for holders
    Apr 2 Immunome: An Oncology Powerhouse In The Making
    Mar 28 Immunome GAAP EPS of -$5.38
    Mar 28 Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
    Mar 26 Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
    Mar 26 Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
    Mar 22 Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions
    See more IMNM news...

    Comments

    T

    TraderMike 3 months ago

    I was in the right place at the right time on this today. 🎉  I actually bought it yesterday after it made a (you guessed it) 
    Non-ADX 1,2,3,4 Bullish     signal the day before.  I sold half around 21 and am still holding the other half of the shares.  

    0 Reply
    View full discussion...

    Indicators

    Indicator Value
    52 Week High 30.958
    52 Week Low 4.44
    Average Volume 798,228
    200-Day Moving Average 12.63
    50-Day Moving Average 22.12
    20-Day Moving Average 18.93
    10-Day Moving Average 16.63
    Average True Range 1.37
    RSI (14) 21.88
    ADX 28.05
    +DI 13.00
    -DI 37.19
    Chandelier Exit (Long, 3 ATRs) 22.60
    Chandelier Exit (Short, 3 ATRs) 17.92
    Upper Bollinger Bands 24.68
    Lower Bollinger Band 13.18
    Percent B (%b) 0.09
    BandWidth 60.79
    MACD Line -2.17
    MACD Signal Line -1.61
    MACD Histogram -0.5625
    Fundamentals Value
    Market Cap 642.1 Million
    Num Shares 45 Million
    EPS -1.80
    Price-to-Earnings (P/E) Ratio -7.92
    Price-to-Sales 105.68
    Price-to-Book 174.08
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.44
    Resistance 3 (R3) 15.43 15.02 15.24
    Resistance 2 (R2) 15.02 14.72 15.03 15.18
    Resistance 1 (R1) 14.64 14.53 14.83 14.65 15.11
    Pivot Point 14.23 14.23 14.33 14.24 14.23
    Support 1 (S1) 13.85 13.93 14.04 13.87 13.41
    Support 2 (S2) 13.44 13.74 13.45 13.34
    Support 3 (S3) 13.06 13.44 13.28
    Support 4 (S4) 13.08